Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis is a research paper published in Trends in Molecular Medicine (2020). On theSindex it has a DataRank of 0.345. It has been cited 9 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCATS NIH HHS
Grant: UL1 TR002319
National Institutes of Health
Grant: P30 DK 089507
National Institutes of Health
Grant: 5P30DK089507-02
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis
National Institutes of Health
Grant: 3UL1TR002319-02S1
Transform Dissemination and Implementation Science in CTSA Programs
CF
Cystic Fibrosis Foundation
FWCI
0.77
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals